ArticleCurrent microbiology2026
In Vivo Assessment of Antimicrobial Potential of Synthetic ANLP-V3 Peptide for the Treatment of Mastitis in a Mouse Model.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic intervention in bovine mastitis faces significant challenges, primarily due to antimicrobial resistance (AMR) and formation of biofilms by etiological agents. Staphylococcus aureus (S. aureus), the most prevalent causative agent, has led to constant antibiotics failure due to development of multidrug-resistant (MDR) strains. Antimicrobial peptides (AMPs) have appeared as promising alternate. The current study evaluated AMP, ANLP-V3, for its therapeutic efficacy against mastitis induced by MDR S. aureus ATCC 700699 ex vivo in milk and in vivo mouse model. ANLP-V3 exhibited bactericidal nature in Minimum Bactericidal Concentration (MBC) assay and time dependent antibacterial activity in UHT milk. Thirty-six lactating Swiss albino mice were randomly divided into 6 groups (n = 6 per group) and infused by intramammary route. Groups I, II, and III were administered with normal saline, S. aureus ATCC 700699, and ANLP-V3 (100 µg), respectively. Groups IV, V, and VI were administered with ANLP-V3 prior infection, co-infusion with infection, and post-infection, respectively. All treatment groups showed approximately 1 log
Indexed as
Identifiers
42268315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.